AIM: To study the clinical efficacy of Conbercept intravitreal injection(0.5mg/0.05mL)in the treatment of exudative age-related macular degeneration(ARMD).

METHODS: Forty-five patients(45 eyes)with exudative age-related macular degeneration diagnosed in our hospital from July 2015 to January 2016 were retrospectively studied. A monthly intravitreal injection of conbercep was carried out. After 3-month injection, conbercep was given if necessary(3+PRN), and all patients were followed up for 2a. Before and after treatment, the intraocular pressure, the best corrected visual acuity(BCVA), central macular thickness(CMT)changes were observed.

RESULTS: The BCVA at 1, 2, 3mo, 1 and 2a after treatment was better than that before treatment(t=5.208, 5.111, 4. 323, 4.701, 5.156; P<0.05). CMT was significantly lower than before treatment(t=3.807, 4.556, 2.841, 2.707, 3.145; P<0.05).

CONCLUSION: Conbercept injection, as 3+PRN, can effectively improve visual acuity, reduce macular edema.